Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lululemon (LULU) downgraded to Equal Weight from Overweight at Wells Fargo with analyst Ike Boruchow saying he sees a balanced risk/reward profile following the recent rally in the shares. 2. Cboe Global Markets (CBOE) downgraded to Neutral from Overweight at JPMorgan with analyst Kenneth Worthington saying trading volumes and open interest "as a leading indicator remain tepid." 3. Cognex (CGNX) downgraded to Underperform from Neutral at Baird with analyst Richard Eastman saying his price target represents a generous trough multiple and he believes it is generous across the Street for an attractive but cyclical-growth technology company. 4. Evolent Health (EVH) downgraded to Neutral from Overweight at Cantor Fitzgerald with analyst Steven Halper citing the company's announcement on Friday that Passport was not successful in its Kentucky Medicaid rebid. 5. Novus Therapeutics (NVUS) downgraded to Neutral from Buy at Ladenburg with analyst Michael Higgens saying while the first exploratory trial with OP0201 met the safety endpoint, OP0201 just missed statistical significance on the 12-to-14 day endpoint while only numerically superior on the 4-to-6 day endpoint. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.